Skip to main content

Anbio Biotechnology

corporate_fare Company Profile

Anbio Biotechnology

NNNN·NASDAQ·Healthcare·CIK 0001982708

Anbio Biotechnology develops and supplies in vitro diagnostics (IVD) products. The company aims to transform the diagnostics landscape globally by providing personalized and decentralized diagnostic solutions. Anbio Biotechnology's portfolio includes IVD products for over-the-counter (OTC) utilization, point-of-care (POCT) settings, and laboratory applications. These products are designed to detect biomarkers related to infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Anbio's IVD products are compatible with multiple sample collection matrices, including serum, plasma, whole blood, feces, urine, and saliva. The company collaborates with third-party laboratories to develop IVD products for laboratory, POCT, and OTC markets, utilizing established IVD technology platforms. Anbio contributes experimental designs, result interpretations, and scientific expertise to guide the laboratory work, and all intellectual property from these collaborations is owned by Anbio.

Anbio Biotechnology (NASDAQ:NNNN) is a publicly traded company in the Healthcare sector. Wiseek monitors NNNN SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Shareholders Approve Drastic Capital Restructuring: Reverse Split, Trillions in New Shares, and Enhanced Insider Control
  • Shareholders to Vote on Reverse Split, Massive Share Authorization, and Super-Voting Share Entrenchment
  • Anbio Biotechnology Reports Strong 2025 Net Income & Gross Margin Amidst Cash Burn and Auditor Change
  • Anbio Biotechnology Changes Auditor Due to Capacity Concerns, Appoints GGF CPA LTD
  • Anbio Biotechnology Appoints Michael Zhang as Independent Director and Audit Committee Chair

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$8.65M
Net Income
$6.4M
Diluted EPS
$0.15
Op. Cash Flow
-$6.74M
Gross Profit
$7.54M
Operating Income
$5.77M
Cash & Equivalents
$7.77M
Debt / Equity
0.00×
Net Margin
74.1%
Shares Outstanding
43.67M sh
Source: 20-F · filed 2026-04-09 · accession 0001185185-26-001313

Insider Transactions

NNNN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with N →
$16.01 -0.43% today
52-week range · as of 2026-05-19 $7.03 – $55.65
Market cap
$2.37B
Volume
55K (2.0× avg)
3-mo avg 27.2K
Live data · 2026-06-12 13:02 UTC · Pre-market

show_chartPrice Chart

Loading chart...

feed NNNN - Latest Insights

NNNN
May 19, 2026, 6:00 AM EDT
Filing Type: 6-K
Importance Score:
9
Shareholders Approve Drastic Capital Restructuring: Reverse Split, Trillions in New Shares, and Enhanced Insider Control
Price at Filing: $28.15
Real-time Price: $16.01 info
Change: -$12.14 (-43%) info
Market Cap: $2.366B info
Sentiment: Negative
View Wiseek Article
NNNN
Apr 27, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
9
Shareholders to Vote on Reverse Split, Massive Share Authorization, and Super-Voting Share Entrenchment
Price at Filing: $27.65
Real-time Price: $16.01 info
Change: -$11.64 (-42%) info
Market Cap: $2.366B info
Sentiment: Negative
View Wiseek Article
NNNN
Apr 07, 2026, 4:15 PM EDT
Filing Type: 20-F
Importance Score:
8
Anbio Biotechnology Reports Strong 2025 Net Income & Gross Margin Amidst Cash Burn and Auditor Change
Price at Filing: $27.37
Real-time Price: $16.01 info
Change: -$11.36 (-42%) info
Market Cap: $2.366B info
Sentiment: Negative
View Wiseek Article
NNNN
Feb 17, 2026, 4:30 PM EST
Filing Type: 6-K
Importance Score:
7
Anbio Biotechnology Changes Auditor Due to Capacity Concerns, Appoints GGF CPA LTD
Price at Filing: $23.75
Real-time Price: $16.01 info
Change: -$7.74 (-33%) info
Market Cap: $2.366B info
Sentiment: Neutral
View Wiseek Article
NNNN
Jan 26, 2026, 6:30 AM EST
Filing Type: 6-K
Importance Score:
7
Anbio Biotechnology Appoints Michael Zhang as Independent Director and Audit Committee Chair
Price at Filing: $30.12
Real-time Price: $16.01 info
Change: -$14.11 (-47%) info
Market Cap: $2.366B info
Sentiment: Positive
View Wiseek Article